The Distinct Biological Effects of 6-Hydroxy-L-Nicotine in Representative Cancer Cell Lines

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Dec 17

PMID 39683752

Authors

Paula Alexandra Postu

Razvan Stefan Boiangiu

Marius Mihasan

Alexandru Bogdan Stache

Adrian Tiron

Lucian Hritcu

Affiliations

Soon will be listed here.

Abstract

6-hydroxy-L-nicotine (6HLN) is a nicotine (NIC) derivative with proven therapeutic potential in neurodegenerative disorders. Here, the impact of 6HLN on cell growth, migratory behavior, and inflammatory status of three different cancer cell lines (A549, MCF7, and U87) and two normal cell lines (16HBE14o and MCF10A) was investigated. In silico analyses were conducted to evaluate the binding affinity of 6HLN to nicotinic receptors (nAChRs) containing α9 and α5 subunits. The obtained in silico data revealed that 6HLN might act on the cholinergic system. Interestingly, the in vitro data showed the compound has cancer-stimulatory effects in U87 glioblastoma cells and cancer-inhibitory effects in MCF7 breast cancer cells. In A549 lung cancer cells, no changes were detected upon 6HLN administration. More importantly, 6HLN appears not to be deleterious for normal cells, with the viability of 16HBE14o pulmonary cells and MCF10A mammary cells remaining unchanged.

References

Winkler F, Venkatesh H, Amit M, Batchelor T, Demir I, Deneen B . Cancer neuroscience: State of the field, emerging directions. Cell. 2023; 186(8):1689-1707. PMC: 10107403. DOI: 10.1016/j.cell.2023.02.002. View

Ozleyen A, Yilmaz Y, Donmez S, Atalay H, Antika G, Tumer T . Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention. J Cancer Res Clin Oncol. 2022; 149(5):2095-2113. PMC: 9310000. DOI: 10.1007/s00432-022-04187-8. View

Bent R, Moll L, Grabbe S, Bros M . Interleukin-1 Beta-A Friend or Foe in Malignancies?. Int J Mol Sci. 2018; 19(8). PMC: 6121377. DOI: 10.3390/ijms19082155. View

Murayama M, Takada E, Takai K, Arimitsu N, Shimizu J, Suzuki T . Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells. PLoS One. 2022; 17(1):e0260838. PMC: 8794171. DOI: 10.1371/journal.pone.0260838. View

Li Z, Cho C . Neurotransmitters, more than meets the eye--neurotransmitters and their perspectives in cancer development and therapy. Eur J Pharmacol. 2011; 667(1-3):17-22. DOI: 10.1016/j.ejphar.2011.05.077. View

Pucci S, Zoli M, Clementi F, Gotti C . α9-Containing Nicotinic Receptors in Cancer. Front Cell Neurosci. 2022; 15:805123. PMC: 8814915. DOI: 10.3389/fncel.2021.805123. View

Hritcu L, Ionita R, Motei D, Babii C, Stefan M, Mihasan M . Nicotine versus 6-hydroxy-l-nicotine against chlorisondamine induced memory impairment and oxidative stress in the rat hippocampus. Biomed Pharmacother. 2016; 86:102-108. DOI: 10.1016/j.biopha.2016.12.008. View

Huang Z, Zhang Z, Zhou C, Liu L, Huang C . Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (2020). 2022; 3(2):e144. PMC: 9115588. DOI: 10.1002/mco2.144. View

Bordas A, Cedillo J, Arnalich F, Esteban-Rodriguez I, Guerra-Pastrian L, de Castro J . Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers. Oncotarget. 2017; 8(40):67878-67890. PMC: 5620221. DOI: 10.18632/oncotarget.18948. View

10.

Mucchietto V, Fasoli F, Pucci S, Moretti M, Benfante R, Maroli A . α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. Br J Pharmacol. 2017; 175(11):1957-1972. PMC: 5980168. DOI: 10.1111/bph.13954. View

11.

Ke W, Zhang L, Dai Y . The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer. 2020; 11(4):835-839. PMC: 7113041. DOI: 10.1111/1759-7714.13341. View

12.

Mo R, Zhang J, Chen Y, Ding Y . Nicotine promotes chronic obstructive pulmonary disease via inducing pyroptosis activation in bronchial epithelial cells. Mol Med Rep. 2022; 25(3). PMC: 8809053. DOI: 10.3892/mmr.2022.12608. View

13.

Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y . Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021; 6(1):263. PMC: 8273155. DOI: 10.1038/s41392-021-00658-5. View

14.

Nour M, Hajiasgharzadeh K, Kheradmand F, Asadzadeh Z, Bolandi N, Baradaran B . Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: An emerging targeting candidate. Life Sci. 2021; 278:119557. DOI: 10.1016/j.lfs.2021.119557. View

15.

Lolas G, Bianchi A, Syrigos K . Tumour-induced neoneurogenesis and perineural tumour growth: a mathematical approach. Sci Rep. 2016; 6:20684. PMC: 4748234. DOI: 10.1038/srep20684. View

16.

Boiangiu R, Mihasan M, Gorgan D, Stache B, Petre B, Hritcu L . Cotinine and 6-Hydroxy-L-Nicotine Reverses Memory Deficits and Reduces Oxidative Stress in Aβ-Induced Rat Model of Alzheimer's Disease. Antioxidants (Basel). 2020; 9(8). PMC: 7465470. DOI: 10.3390/antiox9080768. View

17.

Arunrungvichian K, Vajragupta O, Hayakawa Y, Pongrakhananon V . Targeting Alpha7 Nicotinic Acetylcholine Receptors in Lung Cancer: Insights, Challenges, and Therapeutic Strategies. ACS Pharmacol Transl Sci. 2024; 7(1):28-41. PMC: 10789132. DOI: 10.1021/acsptsci.3c00138. View

18.

Jiang S, Hu L, Wang X, Li J, Zhang Z . Neurotransmitters: emerging targets in cancer. Oncogene. 2019; 39(3):503-515. DOI: 10.1038/s41388-019-1006-0. View

19.

Monje M, Borniger J, DSilva N, Deneen B, Dirks P, Fattahi F . Roadmap for the Emerging Field of Cancer Neuroscience. Cell. 2020; 181(2):219-222. PMC: 7286095. DOI: 10.1016/j.cell.2020.03.034. View

20.

Cervantes-Villagrana R, Albores-Garcia D, Cervantes-Villagrana A, Garcia-Acevez S . Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020; 5(1):99. PMC: 7303203. DOI: 10.1038/s41392-020-0205-z. View